Clinical Trials

DermatologicHead & NeckThoracic

163 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

NCT06158958 2025-10-27

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

Phase 1 Terminated

27 enrolled

GenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT05599984 2025-10-20

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

288 enrolled

CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT06109272 2025-08-15

LIVIGNO-2

Phase 2/3 Recruiting

660 enrolled

Phase 2 Active not recruiting

Carcinoma, Hepatocellular

NCT05822752 2025-08-14

LIVIGNO-1

130 enrolled

Carcinoma, Hepatocellular, Neoplasms

NCT03893955 2025-08-12

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 2 Active not recruiting

150 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Triple Negative Breast Neoplasms

NCT06632951 2025-08-11

LIVIGNO-3

150 enrolled

Genitourinary

Carcinoma, Transitional Cell, Neoplasms

NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

GastrointestinalGenitourinaryThoracic

185 enrolled 28 charts

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03821935 2025-05-25

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

BreastGastrointestinalHead & Neck

364 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06487559 2025-03-04

A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Phase 1 Recruiting

20 enrolled

Carcinoma, Hepatocellular

NCT04807972 2025-01-07

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Phase 1 Terminated

40 enrolled

Phase 2 Active not recruiting

Neoplasms, Pancreatic Neoplasms

NCT06119217 2024-12-04

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

194 enrolled

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT03639194 2024-02-09

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

132 enrolled

Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT01946074 2023-12-15

A Study of ABT-165 in Subjects With Solid Tumors

101 enrolled

Neoplasms, Colorectal Neoplasms

NCT04196283 2023-02-27

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms

NCT03071757 2022-04-28

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

BreastDermatologicGastrointestinalGynecologicOther solid neoplasmThoracic

139 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03000257 2022-04-14

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors